In leukemia with a T-cell phenotype, the breakpoints of recurrent chromosomal translocations consistently juxtapose TCR gene-regulatory elements, which are highly active in committed T-cell pro genitors, to the protein-coding sequence of oncogenic transcription factors, which then become aberrantly overexpressed as a result of these translocations. The best characterized of the oncogenic transcription factors involved is TAL1 (also known as SCL). TAL1 is overexpressed as a result of the recurrent t(1;14) translocation or intra-chromosomal deletions in approximately one-fourth of child hood T-cell ALL cases. However, TAL1 is aberrantly expressed in the leukemic cells of 60% of children and 45% of adults with T-cell ALL, implicating additional pathogenic mechanisms leading to TAL1 overexpression. One such recently described mechanism is an activating mutation of a noncoding gene-regulatory element, which is described later in this chapter. TAL1 acts as a master regulatory protein during early hematopoietic development and is required for the generation of all blood cell lineages. However, it does not seem to be required for the generation and function of hematopoietic stem cells (HSCs) during adult hematopoiesis. TAL1 is a bona fide T-cell ALL oncogene, as its aberrant expression in murine T-cell progenitors induces T-cell ALL.
TAL1 binds DNA in complex with other transcription factors including TCF3 (also known as E2A), HEB, LMO1/2, GATA3, RUNX1, and MYB. TAL1 binding can activate or repress the expression of its target genes, and a number of these targets have been implicated in T-cell transformation. In murine T-cell progenitors, TAL1 expression inhibits TCF3 transcriptional activity, and loss of TCF3 function induces T-cell leukemias in mice, supporting a role for TAL1-mediated inhibition of TCF3 function in leukemogenesis. The TAL1 complex binds and upregulates the expression of several of its own core components, including TAL1, GATA3, RUNX1, and MYB, thus forming a positive feedback loop that reinforces the activity of this oncogenic transcriptional complex. TAL1 also upregulates the expression of TRIB2, a gene whose overexpression in mouse bone marrow cells induces myeloid leukemia and whose expression is required for the survival of TAL1-overexpressing T-cell ALL. Furthermore, TAL1 also upregulates the expression of the microRNA mir223, which promotes leukemic cell survival by downregulating the expression of the FBXW7 tumor suppressor.
The LIM-only domain genes, LMO1 and LMO2, are also involved in recurrent chromosomal translocations in T-cell ALL. These genes encode transcription factors that interact with TAL1 in erythroid cells and in T-cell leukemias. Homozygous disruption of LMO2 in mice phenocopies the hematopoietic defect of TAL1 knock-outs, suggesting that these proteins function together during hematopoietic development. In addition, overexpression of LMO1 and LMO2 in murine thymocytes leads to T-cell transformation and accelerates the onset of leukemias in TAL1 transgenic mice.